mcmmaf

McMMAF is a protective group-conjugated MMAF. MMAF is a potent tubulin polymerization inhibitor.It is a MMAF derivative having a Maleimidocaproyl linker (MC linker), which is ready to conjugate to antibody or other proteins or biopolymers. Mafodotin is a useful agent for make antibody drug conjugate (ADC) for targeted drug delivery.

Cys-McMMAF, the active compound liberated from AlMcMMAF—a humanized anti-5T4 A1 antibody connected to the microtubule-disrupting molecule MMAF through a maleimidocaproyl linker—demonstrates antitumor effectiveness in two mouse tumor models (H1975 and MDA-MB-361-DYT2) [1].

Anti-SLC34A2 (Lifastuzumab)-McMMAF is an antibody-drug conjugate (ADC) composed of the humanized anti-SLC34A2 (sodium-dependent phosphate transporter 2) antibody Lifastuzumab, linked to the protective group maleimidocaproyl, and the tubulin inhibitor MMAF. The toxic component and linker in this ADC are McMMAF. Anti-SLC34A2 (Lifastuzumab)-McMMAF can induce apoptosis and is utilized in cancer research.

Anti-CCL2 (Carlumab)-McMMAF is an antibody-drug conjugate (ADC) composed of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab, linked with the protective group maleimidocaproyl and the tubulin inhibitor MMAF. The cytotoxic molecule and linker in this ADC are McMMAF. Anti-CCL2 (Carlumab)-McMMAF can induce apoptosis and is used in cancer research.

ADC Control Human IgG1-McMMAF is an antibody-drug conjugate (ADC).

Vorsetuzumab mafodotin (SGN‑75) is an auristatin-based, CD70-targeted antibody-drug conjugate (ADC), composed of the humanized monoclonal antibody Vorsetuzumab and the ADC cytotoxic molecule MMAF, and exerts antitumor effects.

Denintuzumab-MMAF, an ADC, combines a CD19-directed antibody with McMMAF and is utilized in researching acute lymphoblastic leukemia.

Depatuxizumab-MMAF, an antibody-drug conjugate (ADC), comprises an EGFR-targeted antibody linked to McMMAF and is utilized in glioblastoma research.